PMID- 15912437
OWN - NLM
STAT- MEDLINE
DCOM- 20050908
LR  - 20151119
IS  - 0340-9937 (Print)
IS  - 0340-9937 (Linking)
VI  - 29
IP  - 6
DP  - 2004 Sep
TI  - [Antiviral therapy in viral heart disease].
PG  - 618-23
AB  - Several investigations showed that in addition to genetic factors also 
      virological and chronic inflammatory aspects are relevant pathogenic mechanisms 
      for the development of dilated cardiomyopathy (DCM). Based on the etiopathogenic 
      importance of viral persistence and chronic myocardial inflammation for disease 
      progression, novel rational therapeutic strategies have been developed. The 
      diagnosis of chronic myocardial inflammation and viral persistence has been a 
      controversial issue for a long time due to diagnostic pitfalls. Detection of 
      persistence of viral genomes with adequate sensitivity and specificity succeeded 
      only by the establishment of sensitive molecular biological techniques such as in 
      situ hybridization and nested polymerase chain reaction (nPCR). By the use of 
      these molecular biological methods, further viruses have been detected in DCM 
      patients in addition to the classic cardiotropic viruses (entero- and 
      adenoviruses), particularly parvovirus B19, human herpes virus type 6 (HHV-6), 
      and Epstein-Barr virus. Considering these different cardiotropic viruses, viral 
      persistence can be proven in > 50% of the DCM patients, consistent with the 
      diagnosis of viral heart disease. This differentiated diagnosis enables, in 
      addition to symptomatic therapy of heart failure, novel rational therapeutic 
      regimens (e. g., beta-interferon) in the setting of randomized trials such as the 
      BICC Study (Betaferon In Patients with Chronic Viral Cardiomyopathy).
FAU - Pauschinger, Matthias
AU  - Pauschinger M
AD  - Medizinische Klinik II, Kardiologie, Campus Benjamin Franklin, 
      Charite-Universitatsmedizin Berlin, Berlin. pauschinger@ukbf.fu-berlin.de
FAU - Noutsias, Michel
AU  - Noutsias M
FAU - Kuhl, Uwe
AU  - Kuhl U
FAU - Schultheiss, Heinz-Peter
AU  - Schultheiss HP
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Antivirale Therapie bei viraler Herzerkrankung.
PL  - Germany
TA  - Herz
JT  - Herz
JID - 7801231
RN  - 0 (Antiviral Agents)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Antiviral Agents/*administration & dosage
MH  - Cardiomyopathy, Dilated/diagnosis/etiology/*prevention & control/*virology
MH  - Humans
MH  - Interferon-beta/*administration & dosage
MH  - Myocarditis/complications/diagnosis/*drug therapy/*virology
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'
MH  - Virus Diseases/complications/diagnosis/drug therapy/virology
RF  - 46
EDAT- 2005/05/25 09:00
MHDA- 2005/09/09 09:00
CRDT- 2005/05/25 09:00
PHST- 2005/05/25 09:00 [pubmed]
PHST- 2005/09/09 09:00 [medline]
PHST- 2005/05/25 09:00 [entrez]
AID - 10.1007/s00059-004-2598-9 [doi]
PST - ppublish
SO  - Herz. 2004 Sep;29(6):618-23. doi: 10.1007/s00059-004-2598-9.